TrialThe oncologist2026

Dose-expansion study of OBI-999, a Globo H-targeting antibody-drug conjugate, in patients with advanced solid tumors.

Apostolia Maria Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.